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Why a Working Group on inherited kidney
disorders?
Dozens of inherited diseases affect the kidney; collectively,
they account for at least 10% of patients with end-stage
renal disease in Europe [1]. The underlying genetic defects
may affect all structures and cell types of the nephron and
may therefore compromise all aspects of kidney function.
In addition, extra-renal involvement is frequently associ-
ated. In terms of frequency, inherited kidney disorders
vary from relatively frequent diseases, such as autosomal
dominant polycystic kidney disease (ADPKD, that argu-
ably affects one in every 1000 person), to ‘rare’ diseases
that, by definition, affect less than five persons in every
10 000.
Inherited kidney diseases concern a large number of pa-
tients in Europe and have a negative impact on the quality
of life of the patients, who are often children, and of family
members and relatives [2–5]. Most of these diseases are
chronically debilitating conditions; some are life threaten-
ing. Low incidence, frequent phenotypic variability, lack of
standardized diagnostic procedures and fragmentation of
clinical and biological data (obtained mostly from small
cohorts) limit our knowledge of many inherited disorders.
These limitations include not only the underlying molec-
ular mechanism(s) of disease but also the natural course
and the impact of the diseases on quality of life, hampering
possibilities to perform clinical studies and hindering pro-
gress in diagnosis and treatment [6, 7]. Furthermore, the
low prevalence of such disorders implies a lack of priority
for the pharmaceutical industry. The uneven perception of
the impact of these diseases on the health care burden is
reflected by discrepancies in public and private funding
schemes across European countries.
As physicians and nephrologists, we recognize the health
care priority represented by inherited kidney diseases in the
community and are committed to improving the medical
treatment of affected individuals.
Post-genomic era: need for exchange and
international networks
The establishment of an unequivocal genetic diagnosis is
essential to define the disease entity, to characterize the
pathophysiology, to screen and stratify patients for observa-
tional and interventional studies, to predict disease course
and outcomes and, ultimately, to improve care, follow-up
and support. The past three decades have witnessed a revo-
lution in molecular biology and genetics that has changed
the way we understand monogenic diseases. More recently,
these changes have also impacted our perception of more
common multigenic disorders. It is now increasingly recog-
nized that genetic factors also influence most aspects of renal
function in the general population and represent important
determinants for the progression of chronic renal failure in
acquired kidney diseases [8–10]. Bioinformatics and
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technical advances in the post-genome era, including rapid
development of next-generation sequencing technologies
(e.g. exome and whole-genome sequencing, with increas-
ingly refined methods to filter the identified variants) have
opened new perspectives for the diagnosis, screening and
pre-symptomatic testing of Mendelian diseases. These ad-
vances are paralleled by more precise in-depth phenotyping
of patients and by the increasing availability of model or-
ganisms, transgenic mice and cell culture systems which
provide insights into the biological role of encoded proteins
and their involvement in disease process. Altogether, these
advances are crucial to improve diagnostic and follow-up
tests, to design new target-based therapeutics and, poten-
tially, to predict response to pharmacotherapy as well as
adverse drug events [5, 11].
The clinical and research community at large is aware of
the necessity to disseminate new scientific knowledge on
rapid advances in technology for molecular diagnosis and
on their consequences (including technical and ethical lim-
itations) for the identification of single gene defects, com-
plex diseases and disorders with oligogenic modes of
inheritance [12, 13]. These efforts require exchange and
networking between patients, patient caregivers, geneti-
cists, clinicians, laboratory scientists and researchers from
the pharmaceutical industry to develop translational ap-
proaches. The latter should involve complementary teams
that are able to cover the spectrum of individual diseases in
terms of clinical investigations, registries, molecular diag-
nosis and modelling/pathophysiology [4, 5, 14]. Patient
organizations should be involved in this effort from the
start [15]; their contribution is essential, in particular in
promoting public awareness and fostering research aimed
at early diagnosis and improved treatment. In times of
budgetary constraints, international networks are also cru-
cial to avoid the fragmentation of knowledge and duplica-
tion of efforts.
Finally, with the identification of an increasing number of
monogenic diseases, it has become evident that insights on
inherited kidney diseases are also relevant for our funda-
mental knowledge of renal physiology/biochemistry and
of more common clinical problems, such as renal disease
progression, blood pressure control, kidney stone formation
and multi-systemic involvement of renal diseases.
Objectives of the Working Group
The creation of the ERA-EDTA Working Group on In-
herited Kidney Disorders (WGIKD) aims at filling a gap
in European nephrology and mobilizing a critical mass of
expertise towards the following objectives:
 to encourage ‘research’, on a Europe-wide scale, on the
natural history and mechanisms of inherited diseases af-
fecting the kidney. These disorders include orphan neph-
ropathies affecting all components of the kidney and
cystic kidney disorders;
 to address the need for ‘epidemiology’ data and regis-
tries, the necessity for earlier and more efficient ‘diag-
nosis’, the identification of new ‘therapeutic targets’ and
improved and affordable care;
 to facilitate the ‘dissemination of knowledge’ to health
care providers, patients and their families, patient support
groups, health authorities and policymakers and industry;
 to organize ‘dedicated meetings’, in conjunction with the
annual ERA-EDTA congress and on specific occasions
(focus on education, ethics, policies and research pro-
posals).
Ultimately, disseminating knowledge, increasing aware-
ness and promoting basic and clinical investigations should
pave the way for a better global care of these disorders
(Figure 1).
Ongoing projects
The activities of the ERA-EDTA WGIKD include:
 a dedicated symposium during the annual ERA-EDTA
Congress as well as during the European Society of
Pediatric Nephrology;
 the elaboration and publication of ‘best practice’ guide-
lines on selected topics of wide interest, in collaboration
with the relevant societies and the European Renal Best
Practice group of the ERA-EDTA;
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Fig. 1. Pathways of translating knowledge on inherited kidney disorders to clinical applications.
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 the organization of continuous medical education semi-
nars in various locations in Europe, targeting local needs;
 the support of research projects addressing critical issues
related to inherited kidney diseases (e.g. the EuroCYST
initiative to create a European cohort of patients with
ADPKD);
 the support for registries, cohorts and recruitment of de-
fined patient groups, and the diffusion of knowledge and
support at a local level.
These activities, as well as specific announcements and
relevant informations, will be posted regularly on the web-
site (http://www.era-edta.org/wgikd/ERA-EDTA_working_
group_on_Inherited_kidney_disorders.htm).
Active communication between the Working Group, or-
ganizations involved in strategic programmes on rare/
inherited kidney diseases, patient support groups and adult
and paediatric nephrology societies in Europe is ongoing.
Membership
The establishment of the ERA-EDTA WGIKD offers the
opportunity to gather individuals concerned by all types of
inherited nephropathies, including ADPKD (which is usu-
ally not considered a rare disease by health policy makers)
across Europe. The Working Group aims at fostering
exchange between adult and paediatric nephrologists, clini-
cians and scientists across disciplines ranging from general
internal medicine to urology and nephrology and genetics
and more fundamental areas of science.
Core members of the Working Group are currently in-
volved in several European Union (EU)-funded projects
addressing kidney diseases (EuReGene, Genecure, EUNE-
FRON, PodoNet, ESCAPE and EuroCYST), in addition to
national and international collaborative efforts in clinical
and fundamental research in inherited kidney disorders.
The body of expertise available in the network should
facilitate a better coordination to diffuse scientific knowl-
edge and raise public awareness for inherited nephropathies
in the EU, in collaboration with patient associations and
public institutions, within the context of policies developed
by the ERA-EDTA. The initial phase of the network
already involves >50 groups, totalizing 2001 participants
from all across Europe.
Enrolment in the Working Group is free and easy
through the ERA-EDTA website (see above) or by sending
an email to wgikd@era-edta.org.
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